Zixuan Wang1, Phoebe W H Ho2, Michael T H Choy2, Ian C K Wong1,2, Ruth Brauer1, Kenneth K C Man3,4,5. 1. Research Department of Practice and Policy, UCL School of Pharmacy, Mezzanine Floor, BMA House, Entrance A, Tavistock Square, London, WC1H 9JP, UK. 2. Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong. 3. Research Department of Practice and Policy, UCL School of Pharmacy, Mezzanine Floor, BMA House, Entrance A, Tavistock Square, London, WC1H 9JP, UK. kenneth.man@ucl.ac.uk. 4. Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong. kenneth.man@ucl.ac.uk. 5. Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands. kenneth.man@ucl.ac.uk.
Abstract
INTRODUCTION: Studies have used various epidemiological approaches to study associations between central nervous system (CNS) drug use in pregnancy and CNS outcomes in children. Studies have generally focused on clinical adverse effects, whereas variations in methodologies have not received sufficient attention. OBJECTIVE: Our objective was to review the methodological characteristics of existing studies to identify any limitations and recommend further research. METHODS: A systematic literature search was conducted on observational studies listed in PubMed from 1 January 1946 to 21 September 2017. Following independent screening and data extraction, we conducted a review addressing the trends of relevant studies, differences between various data sources, and methods used to address bias and confounders; we also conducted statistical analyses. RESULTS: In total, 111 observational studies, 25 case-control studies, and 86 cohort studies were included in the review. Publications dating from 1978 to 2006 mainly focused on antiepileptic drugs, but research on antidepressants increased from 2007 onwards. Only one study focused on antipsychotic use during pregnancy. A total of 46 studies obtained data from an administrative database/registry, 20 from ad hoc disease registries, and 41 from ad hoc clinical samples. Most studies (58%) adjusted the confounding factors using general adjustment, whereas only a few studies used advanced methods such as sibling-matched models and propensity score methods; 42 articles used univariate analyses and 69 conducted multivariable regression analyses. CONCLUSION: Multiple factors, including different study designs and data sources, have led to inconsistent findings in associations between CNS drug use in pregnancy and CNS outcomes in children. Researchers should allow for study designs with clearly defined exposure periods, at the very least in trimesters, and use advanced confounding adjustment methodology to increase the accuracy of the findings.
INTRODUCTION: Studies have used various epidemiological approaches to study associations between central nervous system (CNS) drug use in pregnancy and CNS outcomes in children. Studies have generally focused on clinical adverse effects, whereas variations in methodologies have not received sufficient attention. OBJECTIVE: Our objective was to review the methodological characteristics of existing studies to identify any limitations and recommend further research. METHODS: A systematic literature search was conducted on observational studies listed in PubMed from 1 January 1946 to 21 September 2017. Following independent screening and data extraction, we conducted a review addressing the trends of relevant studies, differences between various data sources, and methods used to address bias and confounders; we also conducted statistical analyses. RESULTS: In total, 111 observational studies, 25 case-control studies, and 86 cohort studies were included in the review. Publications dating from 1978 to 2006 mainly focused on antiepileptic drugs, but research on antidepressants increased from 2007 onwards. Only one study focused on antipsychotic use during pregnancy. A total of 46 studies obtained data from an administrative database/registry, 20 from ad hoc disease registries, and 41 from ad hoc clinical samples. Most studies (58%) adjusted the confounding factors using general adjustment, whereas only a few studies used advanced methods such as sibling-matched models and propensity score methods; 42 articles used univariate analyses and 69 conducted multivariable regression analyses. CONCLUSION: Multiple factors, including different study designs and data sources, have led to inconsistent findings in associations between CNS drug use in pregnancy and CNS outcomes in children. Researchers should allow for study designs with clearly defined exposure periods, at the very least in trimesters, and use advanced confounding adjustment methodology to increase the accuracy of the findings.
Authors: J G Omtzigt; F J Los; D E Grobbee; L Pijpers; M G Jahoda; H Brandenburg; P A Stewart; H L Gaillard; E S Sachs; J W Wladimiroff Journal: Neurology Date: 1992-04 Impact factor: 9.910
Authors: Alexander Viktorin; Rudolf Uher; Alexander Kolevzon; Abraham Reichenberg; Stephen Z Levine; Sven Sandin Journal: JAMA Psychiatry Date: 2017-10-01 Impact factor: 21.596
Authors: Martha M Werler; Katherine A Ahrens; Jaclyn L F Bosco; Allen A Mitchell; Marlene T Anderka; Suzanne M Gilboa; Lewis B Holmes Journal: Ann Epidemiol Date: 2011-11 Impact factor: 3.797
Authors: L B Holmes; E A Harvey; B A Coull; K B Huntington; S Khoshbin; A M Hayes; L M Ryan Journal: N Engl J Med Date: 2001-04-12 Impact factor: 91.245
Authors: Janneke Jentink; Helen Dolk; Maria A Loane; Joan K Morris; Diana Wellesley; Ester Garne; Lolkje de Jong-van den Berg Journal: BMJ Date: 2010-12-02
Authors: Ellen Mawhinney; John Craig; Jim Morrow; Aline Russell; W Henry Smithson; Linda Parsons; Patrick J Morrison; Brenda Liggan; Beth Irwin; Norman Delanty; Stephen J Hunt Journal: Neurology Date: 2013-01-09 Impact factor: 9.910
Authors: Lin Li; Ayesha C Sujan; Agnieszka Butwicka; Zheng Chang; Samuele Cortese; Patrick Quinn; Alexander Viktorin; A Sara Öberg; Brian M D'Onofrio; Henrik Larsson Journal: CNS Drugs Date: 2020-07 Impact factor: 5.749